Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.
LevitzkiA.: Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther, 82: 231–239, 1999.
2.
FryD.W.: Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des, 15: 3–16, 2000.
3.
CarlomagnoF., VitaglianoD., GuidaT., NapolitanoM., VecchioG., FuscoA., GazitA., LevitzkiA., SantoroM.: The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res, 62: 1077–1082, 2002.
